The Pediatric Oncology Program at the University of Wisconsin in Madison is a founding member of CCSG. Over the past five year, we have entered almost 32 patients/year on CCSG therapeutic trials, contributing about 1.5% of Group entries. In the 20 months, between 1/1/86 and 8/31/87, 15/22 """"""""new"""""""" patients with leukemia (68%) and 32/66 """"""""new"""""""" patients with solid tumors (48%) were entered on Group therapeutic trials. We have contributed about 3% of entries to Group Epidemiology and Special studies. Our record for data submission has been excellent. We hope to improve our accruals 1) as new studies open for bone marrow transplant, brain tumor, and late effects; 2) as we improve communication with area physicians; and 3) with the addition of Dr. Timothy Kinsella in Radiation Oncology as Chairman of the Department of Human Oncology and of Dr. John Heiner to the Department of Orthopedic Surgery. The principal contribution of the Pediatric Oncology Program at UW will likely remain in the area of scientific leadership. Drs. michael Trigg and Jonathan Finlay have left the program. Dr. Paul Gaynon has arrived. He has been active in the Group for nine years and will serve as principal investigator. He has had major responsibility for writing 7 protocols and has served as chairman or co-chairman for CCG-085, CCG- 093, CCG-99, CCG-106, CCG-192P, CCG-193P, CCG-321P and CCG-S70. He serves as Coordinator for Front Line ALL trials on the Leukemia Strategy Group and on the New Agents Steering and Computer Committees. Dr. Paul Sondel has been a leader in the investigation of biological therapeutics - especially IL-2 - both in the UW Clinical Cancer Center and in the Group. He serves in the Immunocology Committee and will chair CCG-8609, the planned phase I trial of IL-2. He has co-directed the UW ALL Immunophenotype Resource Laboratory for the Group and is establishing a CCSG IL-2/Biotherapy Resource Laboratory here. Details are provided in the Group Chairman's grant.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA005436-26
Application #
3555846
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1978-12-01
Project End
1993-11-30
Budget Start
1991-12-01
Budget End
1992-11-30
Support Year
26
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Wisconsin Madison
Department
Type
Schools of Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Shamberger, Robert C; LaQuaglia, Michael P; Gebhardt, Mark C et al. (2003) Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy. Ann Surg 238:563-7; discussion 567-8
Davies, Stella M; Bhatia, Smita; Ross, Julie A et al. (2002) Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood 100:67-71
Wells, Robert J; Reid, Joel M; Ames, Matthew M et al. (2002) Phase I trial of cisplatin and topotecan in children with recurrent solid tumors: Children's Cancer Group Study 0942. J Pediatr Hematol Oncol 24:89-93
Lange, Beverly J; Bostrom, Bruce C; Cherlow, Joel M et al. (2002) Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 99:825-33
Ou, Shu Xiao; Han, Dehui; Severson, Richard K et al. (2002) Birth characteristics, maternal reproductive history, hormone use during pregnancy, and risk of childhood acute lymphocytic leukemia by immunophenotype (United States). Cancer Causes Control 13:15-25
Cairo, M S; Krailo, M D; Morse, M et al. (2002) Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate ('Orange') in children with advanced non-lymphoblastic non-Hodgkin's lymphoma: a children's cancer group report. Leukemia 16:594-600
Wells, R J; Arthur, D C; Srivastava, A et al. (2002) Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children's Cancer Group Study 213. Leukemia 16:601-7
Cooper, R; Khakoo, Y; Matthay, K K et al. (2001) Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children's Cancer Group. Med Pediatr Oncol 36:623-9
Teplitzky, S R; Kiefer, T L; Cheng, Q et al. (2001) Chemoprevention of NMU-induced rat mammary carcinoma with the combination of melatonin and 9-cis-retinoic acid. Cancer Lett 168:155-63
Kammen, B F; Matthay, K K; Pacharn, P et al. (2001) Pulmonary metastases at diagnosis of neuroblastoma in pediatric patients: CT findings and prognosis. AJR Am J Roentgenol 176:755-9

Showing the most recent 10 out of 27 publications